Please assess the completion status of the following clinical trial:

Trial Title: Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age is over 20 years old, under 80 years old, men or women~* Patients who had experienced extra-esophageal symptoms of gastroesophageal reflux disease more than once a week within the last month prior to the start of the study~Exclusion Criteria:~* Patients administered with prokinetics, H2 receptor antagonists, proton pump inhibitors, anticholinergic drugs or non-steroid anti-inflammatory drugs prior to study in 4 weeks~* Patients administered with anti-thrombotic drugs~* Patients taking other investigational drugs or participating in other clinical studies in 4 weeks~* Patients with esophageal stricture, esophageal varix, Barrett's esophagus, peptic ulcer or gastrointestinal bleeding~* Patients with Zollinger-Ellison syndrome~* Patients with any kind of malignant tumor~* Patients with surgery related to gastroesophageal~* Patients with significant cardiovascular, pulmonary, heptic, renal, hemopoietic or endocrine system primary disease~* Patients with neuropsychiatric disorder, alcoholism, or drug abuse~* Women either pregnant or breast feeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- High-dose rabeprazole (Type: EXPERIMENTAL): Rabeprazole 20mg twice daily by mouth before breakfast and dinner for 8 weeks
- Standard-dose rabeprazole (Type: ACTIVE_COMPARATOR): Rabeprazole 20mg once daily by mouth before breakfast for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).